Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04980872




Registration number
NCT04980872
Ethics application status
Date submitted
23/07/2021
Date registered
28/07/2021
Date last updated
3/07/2023

Titles & IDs
Public title
A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)
Scientific title
A Multicenter, Open-label, Phase 2, Extension Trial to Study the Long-term Safety in Participants With PROS or Proteus Syndrome Who Are Currently Being Treated With Miransertib in Other Studies
Secondary ID [1] 0 0
MK-7075-006
Secondary ID [2] 0 0
7075-006
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS) 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders
Other 0 0 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Miransertib

Experimental: Miransertib - Participants with either PROS or PS receive miransertib orally once daily between 5 and 35 mg/m^2 based on prior approved dosing for up to 48 cycles. A cycle is 28 days long.


Treatment: Drugs: Miransertib
Miransertib capsules administered orally either 1 hour before or 2 hours after a meal.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of participants experiencing a Serious Adverse Event (SAE)
Timepoint [1] 0 0
Up to approximately 4 years
Primary outcome [2] 0 0
Number of participants discontinuing study treatment due to an Adverse Event (AE)
Timepoint [2] 0 0
Up to approximately 4 years

Eligibility
Key inclusion criteria
- Has PROS or PS and is currently being actively treated with miransertib as part of
Study MK-7075-002 (NCT03094832) or ArQule's Compassionate Use and Extended Access
Program (CU/EAP, NCT03317366)
Minimum age
2 Years
Maximum age
120 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Has previously discontinued miransertib due to related SAEs or other intolerance of
miransertib

- Received other investigational agents, if any, that were administered between leaving
Study MK-7075-02 or ArQule's CU/EAP and entering this trial

- Receives inhibitors of the mechanistic target of rapamycin (mTOR) pathway (eg,
sirolimus, everolimus)

- Receives immunosuppressive therapies

- Receives continuous high dose steroids

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
2/11/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
29/09/2026
Actual
Sample size
Target
60
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Recruitment hospital [1] 0 0
John Hunter Hospital ( Site 0203) - Newcastle
Recruitment hospital [2] 0 0
Bundaberg Base Hospital ( Site 0202) - Bundaberg
Recruitment postcode(s) [1] 0 0
2305 - Newcastle
Recruitment postcode(s) [2] 0 0
4670 - Bundaberg
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Georgia
Country [2] 0 0
United States of America
State/province [2] 0 0
Massachusetts
Country [3] 0 0
United States of America
State/province [3] 0 0
Ohio
Country [4] 0 0
United States of America
State/province [4] 0 0
Texas
Country [5] 0 0
United States of America
State/province [5] 0 0
Washington
Country [6] 0 0
Brazil
State/province [6] 0 0
Goias
Country [7] 0 0
Italy
State/province [7] 0 0
Lazio
Country [8] 0 0
Italy
State/province [8] 0 0
Roma
Country [9] 0 0
United Kingdom
State/province [9] 0 0
London, City Of

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Merck Sharp & Dohme LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a study of the safety and tolerability of oral miransertib (MK-7075) administered to
participants at least 2 years of age with phosphatidylinositol-4,5-bisphosphate 3-kinase
catalytic subunit alpha (PIK3CA)-related overgrowth spectrum (PROS) or Proteus Syndrome (PS).
This is an extension of other miransertib studies (MK-7075-002 [NCT03094832] or ArQule CU/EAP
[NCT03317366]), and may also enroll participants who are approved for MK-7075-002 but have
not yet started miransertib therapy.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04980872
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Merck Sharp & Dohme LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04980872